Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A mouse mutant p53 product recognized by CD4+ and CD8+ T cells

Y Noguchi1, Y T Chen, L J Old

  • 1Ludwig Institute for Cancer Research, New York Unit, Memorial Sloan-Kettering Cancer Center, NY 10021.

Proceedings of the National Academy of Sciences of the United States of America
|April 12, 1994
PubMed
Summary

A specific mutated p53 peptide (234CM) induced CD8+ cytotoxic T cells that target cancer cells. This peptide also stimulated CD4+ T cells and enhanced resistance to Meth A sarcoma challenge in mice.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

T cell assays and MIATA: the essential minimum for maximum impact.

Immunity·2012
Same author

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.

British journal of cancer·2011
Same author

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.

Cancer immunology, immunotherapy : CII·2010
Same author

Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients.

British journal of cancer·2006
Same author

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

Preparative biochemistry & biotechnology·2005
Same author

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR.

British journal of cancer·2005

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • The p53 tumor suppressor protein is frequently mutated in cancer.
  • Meth A sarcoma in BALB/c mice harbors specific missense mutations in p53.
  • Understanding T-cell responses to mutated p53 is crucial for cancer immunotherapy.

Purpose of the Study:

  • To analyze the T-cell response to mutated and wild-type p53 peptides from Meth A sarcoma.
  • To identify specific p53 epitopes that elicit cytotoxic T-cell and helper T-cell responses.
  • To evaluate the potential of p53-derived peptides in cancer immunotherapy.

Main Methods:

  • Synthesis of 24 peptides containing wild-type or mutated sequences of Meth A p53.
  • In vitro sensitization of mouse spleen cells with p53 peptides.

Related Experiment Videos

  • Cytotoxicity assays using peptide-pulsed or transfected P1-HTR cells as targets.
  • T-cell proliferation assays to assess CD4+ T-cell responses.
  • In vivo tumor challenge experiments in mice.

    • Main Results:

    • A nonamer peptide with the codon 234 mutation (234CM) induced CD8+ cytotoxic T cells recognizing H-2Kd-restricted targets.
    • CD8+ T-cell lysis was specific for the 234CM peptide and enhanced by interferon-gamma treatment of target cells.
    • Both 234CM and its wild-type counterpart (234CW) elicited CD4+ T-cell proliferation with broader peptide specificity.
    • Immunization with 234CM peptide conferred heightened resistance to Meth A sarcoma challenge in mice.

    Conclusions:

    • The codon 234 mutation in Meth A p53 generates a specific epitope recognized by CD8+ cytotoxic T cells.
    • p53-derived peptides can induce both cellular and humoral immune responses.
    • Targeting mutated p53 with specific peptides holds promise for developing novel cancer immunotherapies.